# A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

> **NCT04929223** · PHASE1 · RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 542 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Inavolisib
- **DRUG:** Bevacizumab
- **DRUG:** Cetuximab
- **DRUG:** Atezolizumab
- **DRUG:** Tiragolumab
- **DRUG:** SY-5609
- **DRUG:** Divarasib
- **DRUG:** FOLFOX
- **DRUG:** FOLFIRI
- **DIAGNOSTIC_TEST:** FoundationOne®Liquid CDx

## Key facts

- **NCT ID:** NCT04929223
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-10-22
- **Primary completion:** 2030-08-31
- **Final completion:** 2030-08-31
- **Target enrollment:** 542 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04929223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04929223, "A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04929223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*